Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Boston Scientific

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Boston Scientific

Regulatory records
5
Linked recall entries
0
Headquarters
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 5 FDA records to the applicant name Boston Scientific. The collection includes 1 510(k) clearance. It includes 2 original PMA approvals. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 26, 1993 to Oct 3, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LWP appears in 2 of the 5 linked filings. The collection spans 3 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P150012, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 4 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 4100 Hamline Ave. N, St Paul, MN, 55112. Recorded on P150012/S191, decision dated Oct 3, 2026.

Changes described in PMA records

P150012/S191: ESSENTIO MRI (Model L131); PROPONENT MRI (Model L231); ACCOLADE MRI (Model L331); ESSENTIO MRI (Models L110, L111); PRO

The FDA record P150012/S191 lists Boston Scientific as applicant for a 30-Day Notice supplement to PMA P150012, decided OK30 on 2026-10-03. The reported statement describes two manufacturing-related actions: implementing an additional acceptance activity for Accolade SL batteries and changing a specification for an existing Accolade EL battery specification. The device category is implantable pulse generator, pacemaker (non-CRT), product code LWP.

The action concerns battery acceptance and specification items, not a new approval of the whole system. The record does not identify which acceptance activity was added, what the revised EL specification is, or what validation data supported either change, so those details remain absent and the statement's purpose is not evidence of safety or clinical effectiveness.

FDA approval-order wording

to implement an additional acceptance activity for Accolade SL batteries and to change a specification for an existing Accolade EL battery specification

Oct 3, 2026 · 30-Day Notice

P910073/S193: ENDOTAK LEAD SYSTEM

FDA’s recorded scope: approval for supplemental labeling for the ENDOTAK RELIANCE ePTFE family of defibrillator leads to align with a July 2025 Product Advisory.

Sep 17, 2026 · Special (Immediate Track)

P150012: IMAGEREADY MR CONDITIONAL PACING SYSTEM AND INGEVITY PACE/SENSE LEAD

FDA approved Boston Scientific's ImageReady MR Conditional Pacing System under P150012 on April 25, 2016. The approval covers pacing indications for symptomatic AV block, bundle branch block, sinus node dysfunction, bradycardia-tachycardia syndrome, and neurovascular or carotid sinus syndromes, plus adaptive-rate pacing for chronotropic incompetence. Dual-chamber and atrial tracking modes are indicated for maintaining AV synchrony, VVI intolerance, and low cardiac output or congestive heart failure secondary to bradycardia.

The approval also covers Ingevity pace/sense leads. Passive-fixation non-MRI models 7631, 7632, 7635, 7636 and MRI models 7731, 7732, 7735, 7736 are indicated for chronic pacing and sensing in the right atrium (Preformed Atrial J) or right ventricle (Straight). Active-fixation non-MRI models 7640, 7641, 7642 and MRI models 7740, 7741, 7742 are indicated for chronic pacing and sensing in the right atrium and/or right ventricle. Accessories include a slit suture sleeve and delivery stylet.

FDA approval-order wording

Approval for The ImageReady MR Conditional Pacing System. The device is indicated for the treatment of the following conditions:1) Symptomatic paroxysmal or permanent second- or third-degree AV block;2) Symptomatic bilateral bundle branch block;3) Symptomatic paroxysmal or transient sinus node dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia, sinus arrest, sinoatrial [SA] block);4) Bradycardia-tachycardia syndrome, to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias; and5) Neurovascular (vaso-vagal) syndromes or hypersensitive carotid sinus syndromes.Adaptive-rate pacing is indicated for patients exhibiting chronotropic incompetence and who may benefit from increased pacing rates concurrent with increases in minute ventilation and/or level of physical activity.Dual-chamber and atrial tracking modes are also indicated for patients who may benefit from maintenance of AV synchrony.Dual chamber modes are specifically indicated for treatment of the following:1) Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block;2) VVI intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm; and3) Low cardiac output or congestive heart failure secondary to bradycardia. Passive-fixation Non-MRI Models 7631, 7632, 7635 and 7636 and MRI Models 7731, 7732, 7735 and 7736 are indicated for chronic pacing and sensing in the right atrium (Preformed Atrial J) or right ventricle (Straight) when used with a compatible pulse generator.Active-fixation Non-MRI Models 7640, 7641, and 7642 and MRI Models 7740, 7741, and 7742 are indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.The intended use of the slit suture sleeve accessory is to secure and immobilize Boston Scientific Ingevity leads at the venous entry site.The delivery stylet accessory is indicated for use with Boston Scientific implantable transvenous leads.

Apr 25, 2016

P910073: ENDOTAK LEAD SYSTEM

FDA approved the 0060 Series ENDOTAK Lead System on August 26, 1993. The system includes ENDOTAK C Lead Models 0060, 0062, and 0064; Lead Stylet Models 6824 and 6825; ENDOTAK SQ Patch Lead Model 0063; a commercially available AICD Y Connector Model 6836; and Model 0056 Bipolar Positive Fixation Lead and Adapter. It is a transvenous defibrillation leads system used with commercially available AICD Models 15050, 1555, and 1600.

The statement describes the system as intended for treating ventricular tachyarrhythmias in patients at high risk of sudden cardiac death, defined by prior cardiac arrest or inducible sustained hypotensive VT or VF despite conventional antiarrhythmic drug therapy. The statement notes the system does not require a thoracotomy, but physicians should weigh that against possible additional EP testing or thoracotomy if the leads prove ineffective. The SQ Patch Lead is intended only for chronic subcutaneous or submuscular implantation with an ENDOTAK C Lead, not epicardial or pericardial placement.

FDA approval-order wording

Approval for the 0060 Series ENDOTAK Lead System. The ENDOTAK Lead System (hereafter referred to as the ENDOTAK Lead System) consists of the following: the ENDOTAK C Lead Models 0060, 0062, 0064; Lead Stylet Models 6824 and 6825; ENDOTAK SQ Patch Lead Model 0063; commercially available AICD Y Connector Model 6836; and Model 0056 Bipolar Positive Fixation Lead and Adapter. The ENDOTAK Lead System is used with commercially available AICD Models 15050, 1555, and 1600. The ENDOTAK Lead System is a transvenous defibrillation leads system and is intended for the treatment of ventricular tacharrhythmias in patients who are at high risk of sudden cardiac death. Such patients are defined as those who have experienced one or more of the following: (1) survived at least one episode of cardiac arrest presumable due to hemodynamically unstable ventricular tachyarrhythmias unassociated with acute myocardial infarction; or (2) recurrent ventricular tachyarrhythmias in the absence of such previous arrest and are inducible into sustained hypotensive ventricular tachycardia (VT) or ventricular fibrillation (VF) despite conventional antiarrhythmic drug therapy.A major consideration in choosing the ENDOTAK Lead System is that it does not require a thoracotomy. The physician should weigh its advantages against the patients ability to withstand additional electrophysiological (EP) testing (arrhythmia induction and conversion testing), and a possible thoracotomy, should the lead system prove ineffective.Various factors such as cardiomegaly or drug therapy may necessitate repositioning of the defibrillating leads, or substitution of one lead system for another in order to facilitate arrhythmia conversion. In some cases, reliable arrhythmia conversion may not be obtained with any leads at the available AICD energy levels.Bipolar pacmakers may be used with the ENDOTAK Lead System and AICD pulse generator as long as the pacemaker and AICD pulse generator do not interact causing AICD pulse generator nondetection or false detection.The ENDOTAK SQ Patch Lead is intended for chronic subcutaneous or submuscular implantation in conjunction with an ENDOTAK C Lead. The ENDOTAK SQ Patch Leas is not intended for epicardial or pericardial placement.

Aug 26, 1993

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Boston ScientificPMA supplementOct 3, 2026FDA
Boston ScientificPMA supplementSep 17, 2026FDA
Boston Scientific510(k) clearanceSep 3, 2026FDA
Boston ScientificPMA approvalApr 25, 2016FDA
Boston ScientificPMA approvalAug 26, 1993FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.